Use este identificador para citar ou linkar para este item:
Tipo de documento
ArtigoDireito Autoral
Acesso aberto
Objetivos de Desenvolvimento Sustentável
03 Saúde e Bem-EstarColeções
Metadata
Mostrar registro completo
IMMUNOGENICITY OF PVCYRPA, PVCELTOS AND PVS25 CHIMERIC RECOMBINANT PROTEIN OF PLASMODIUM VIVAX IN MURINE MODEL
Multistage chimeric protein
Immunization
BALB/c
In silico simulation
Vaccine
Immunogenicity
Produção científica do Laboratório de Imunoparasitologia.
Produção científica do Laboratório de Pesquisa em Malária.
Autor(es)
Afiliação
Resumo em Inglês
In the Americas, P. vivax is the predominant causative species of malaria, a debilitating and economically significant disease. Due to the complexity of the malaria parasite life cycle, a vaccine formulation with multiple antigens expressed in various parasite stages may represent an effective approach. Based on this, we previously designed and constructed a chimeric recombinant protein, PvRMC-1, composed by PvCyRPA, PvCelTOS, and Pvs25 epitopes. This chimeric protein was strongly recognized by naturally acquired antibodies from exposed population in the Brazilian Amazon. However, there was no investigation about the induced immune response of PvRMC-1. Therefore, in this work, we evaluated the immunogenicity of this chimeric antigen formulated in three distinct adjuvants: Stimune, AddaVax or Aluminum hydroxide (Al(OH)3) in BALB/c mice. Our results suggested that the chimeric protein PvRMC-1 were capable to generate humoral and cellular responses across all three formulations. Antibodies recognized full-length PvRMC-1 and linear B-cell epitopes from PvCyRPA, PvCelTOS, and Pvs25 individually. Moreover, mice’s splenocytes were activated, producing IFN-γ in response to PvCelTOS and PvCyRPA peptide epitopes, affirming T-cell epitopes in the antigen. While aluminum hydroxide showed notable cellular response, Stimune and Addavax induced a more comprehensive immune response, encompassing both cellular and humoral components. Thus, our findings indicate that PvRMC-1 would be a promising multistage vaccine candidate that could advance to further preclinical studies.
Palavras-chave em inglês
Plasmodium vivaxMultistage chimeric protein
Immunization
BALB/c
In silico simulation
Vaccine
Immunogenicity
Editor
Frontiers Media
Referência
MATOS, Ada da Silva et al. Immunogenicity of PvCyRPA, PvCelTOS and Pvs25 chimeric recombinant protein of Plasmodium vivax in murine model. Frontiers in Immunology, v. 15, p. 1-15, 19 June 2024.DOI
10.3389/fimmu.2024.1392043ISSN
1664-3224Notas
Produção científica do Laboratório de Hantaviroses e Rickettsioses.Produção científica do Laboratório de Imunoparasitologia.
Produção científica do Laboratório de Pesquisa em Malária.
Compartilhar